Novel CRISPR-Cas9 treatments are proving effective in reversing disease for life. But ensuring their long-term safety will ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday.

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

This figure illustrates the evolution of CRISPR technology from 1987 to 2019, presented in a horizontal timeline format and categorized into four generations, each denoted by a distinct color: The ...

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

Scientists at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, have found that gene editing using CRISPR-Cas9 in combination with AAV6 vectors can trigger inflammatory and ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Best ARK Stocks to Buy Right Now. On May 4, CRISPR Therapeutics AG (NASDAQ:CRSP) reported its first quarter 2026 results and advanced its pipeline ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...